{"id":995207,"date":"2026-08-13T16:54:15","date_gmt":"2026-08-13T20:54:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-announces-second-quarter-2026-financial-results\/"},"modified":"2026-08-13T16:54:15","modified_gmt":"2026-08-13T20:54:15","slug":"nektar-therapeutics-announces-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-announces-second-quarter-2026-financial-results\/","title":{"rendered":"Nektar Therapeutics Announces Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN FRANCISCO<\/span>, Aug. 13, 2026<\/span> \/PRNewswire\/ — Nektar Therapeutics\u00a0(Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today\u00a0reported financial results for the second quarter ended June 30, 2026.<\/p>\n

\n

\n \"Nektar\n <\/p>\n<\/p><\/div>\n

Cash and investments in marketable securities on\u00a0June 30, 2026,\u00a0were\u00a0$1,023.4 million\u00a0as compared to\u00a0$245.8 million\u00a0on\u00a0December 31, 2025.\u00a0<\/p>\n

\n “This year continues to be a transformative year for <\/span>
\n Nektar as we advance our lead program, rezpegaldesleukin, into Phase 3 clinical trials,” said Howard W. Robin, President and Chief Executive Officer of Nektar. <\/span>
\n “We initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July, and we plan to start a single registrational<\/span>
\n Phase <\/span>
\n 3 study in <\/span>
\n alopecia areata<\/span>
\n in early 2027. Our Phase 3 program establishes a clear<\/span>
\n path to the first BLA submission for <\/span>
\n rezpegaldesleukin in 2029. With its novel T-reg mechanism, rezpegaldesleukin is uniquely positioned to provide benefit for patients across a number of chronic autoimmune conditions. Importantly, our financial position is strong with over one billion dollars in cash and investments at the end of the quarter, and a cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028.”<\/span>\n <\/p>\n

Revenue in the second quarter of 2026 was $10.1 million as compared to $11.2 million in the second quarter of 2025. Revenue for the first half of 2026 was $21.0 million as compared to $21.6 million in the first half of 2025.<\/p>\n

Total operating costs and expenses in the second quarter of 2026 were $52.5 million as compared to $47.4 million in the second quarter of 2025. Total operating costs and expenses were $102.4 million for both the first half of 2026 and first half of 2025. Operating expenses for the second quarter and first half of 2026 reflect an increase in R&D expenses, offset by a decrease in G&A expenses.<\/p>\n

R&D expense in the second quarter of 2026 was $39.1 million as compared to $29.9 million for the second quarter of 2025. R&D expense in the first half of 2026 was $74.8 million as compared to $60.4 million for the first half of 2025. R&D expense increased primarily due to the commencement of activities to support the Phase 3 ZENITH AD program in atopic dermatitis as well as manufacturing activities associated with rezpegaldesleukin.<\/p>\n

G&A expense was $12.8 million in the second quarter of 2026 as compared to $17.1 million in the second quarter of 2025. G&A expense was $26.2 million in the first half of 2026 as compared to $41.4 million in the first half of 2025. G&A expense decreased primarily due to a decrease in legal expenses.<\/p>\n

Our non-cash loss from our equity method investment in Gannet BioChem was $0.3 million in the second quarter of 2026, as compared to $2.4 million in the second quarter of 2025. The non-cash loss from the equity method investment was $2.1 million in the first half of 2026, as compared to $6.8 million in the first half of 2025.<\/p>\n

Net loss for the second quarter of 2026 was $40.6 million or $1.23 basic and diluted net loss per share as compared to net loss of $41.6 million or $2.95 basic and diluted loss per share in the second quarter of 2025. Net loss in the first half of 2026 was $85.5 million or $2.96 basic and diluted net loss per share as compared to a net loss of $92.5 million or $6.57 basic and diluted loss per share in the first half of 2025.<\/p>\n

\n Second Quarter 2026 Business Highlights<\/b>\n <\/p>\n